The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Aryx Therapeutics are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak
Strong
Over the last 90 days Aryx Therapeutics I has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Aryx Therapeutics is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
Aryx
Aryx Therapeutics Relative Risk vs. Return Landscape
If you would invest 0.05 in Aryx Therapeutics I on November 8, 2025 and sell it today you would earn a total of 0.00 from holding Aryx Therapeutics I or generate 0.0% return on investment over 90 days. Aryx Therapeutics I is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Aryx, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
Expected Return
Risk
Aryx Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Aryx Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Aryx Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Aryx Therapeutics generated a negative expected return over the last 90 days
Aryx Therapeutics has some characteristics of a very speculative penny stock
Aryx Therapeutics has a very high chance of going through financial distress in the upcoming years
The company has a current ratio of 0.46, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Aryx Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Aryx Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aryx Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aryx to invest in growth at high rates of return. When we think about Aryx Therapeutics' use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (33.17 M) with profit before overhead, payroll, taxes, and interest of 0.
Aryx Therapeutics I currently holds about 2.95 M in cash with (34.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Aryx Therapeutics Fundamentals Growth
Aryx Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Aryx Therapeutics, and Aryx Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aryx Pink Sheet performance.
Evaluating Aryx Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Aryx Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Aryx Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. ARYx Therapeutics, Inc. was founded in 1997 and is based in Fremont, California. ARYX THERAPEUTICS operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on PNK Exchange. It employs 56 people.
Things to note about Aryx Therapeutics performance evaluation
Checking the ongoing alerts about Aryx Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Aryx Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Aryx Therapeutics generated a negative expected return over the last 90 days
Aryx Therapeutics has some characteristics of a very speculative penny stock
Aryx Therapeutics has a very high chance of going through financial distress in the upcoming years
The company has a current ratio of 0.46, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Aryx Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Aryx Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aryx Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aryx to invest in growth at high rates of return. When we think about Aryx Therapeutics' use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (33.17 M) with profit before overhead, payroll, taxes, and interest of 0.
Aryx Therapeutics I currently holds about 2.95 M in cash with (34.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Evaluating Aryx Therapeutics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Aryx Therapeutics' pink sheet performance include:
Analyzing Aryx Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aryx Therapeutics' stock is overvalued or undervalued compared to its peers.
Examining Aryx Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
Evaluating Aryx Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aryx Therapeutics' management team can help you assess the Company's leadership.
Pay attention to analyst opinions and ratings of Aryx Therapeutics' pink sheet. These opinions can provide insight into Aryx Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Aryx Therapeutics' pink sheet performance is not an exact science, and many factors can impact Aryx Therapeutics' pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Additional Tools for Aryx Pink Sheet Analysis
When running Aryx Therapeutics' price analysis, check to measure Aryx Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aryx Therapeutics is operating at the current time. Most of Aryx Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aryx Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aryx Therapeutics' price. Additionally, you may evaluate how the addition of Aryx Therapeutics to your portfolios can decrease your overall portfolio volatility.